Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g., ibrutinib) and a BET inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B cell malignancy, or a MYC-driven B cell malignancy comprising administering a combination of a BTK inhibitor (e.g., ibrutinib) and a BET inhibitor. Further disclosed herein are methods of evaluating a patient having a B-cell malignancy for treatment with a combination of a BTK inhibitor (e.g., ibrutinib) and a BET inhibitor based on the MYC expression level of the patient.本文揭示用於治療B細胞惡性病之方法、組成物、及套組，該治療包含投予BTK抑制劑(例如，依魯替尼(ibrutinib))及BET抑制劑之組合。本文亦揭示用於治療抗BTK B細胞惡性病、或MYC驅動B細胞惡性病之方法、組成物、及套組，該治療包含投予BTK抑制劑(例如，依魯替尼)及BET抑制劑之組合。本文進一步揭示評估具有B細胞惡性病之患者用於BTK抑制劑(例如，依魯替尼)及BET抑制劑之組合治療之方法，該評估基於該患者之MYC表現程度。
